Tafenoquine for relapsing babesiosis: A case series Journal Article
| Authors: | Krause, P. J.; Rogers, R.; Shah, M. K.; Kang, H.; Parsonnet, J.; Kodama, R.; Vannier, E. |
| Article Title: | Tafenoquine for relapsing babesiosis: A case series |
| Abstract: | Background. Relapsing babesiosis often occurs in highly immunocompromised patients and has been attributed to the acquisition of resistance against drugs commonly used for treatment such as atovaquone, azithromycin, and clindamycin. Tafenoquine, which is approved for malaria prophylaxis and presumptive antirelapse treatment of Plasmodium vivax malaria, has shown activity against Babesia microti in several animal models of acute infection and in a single human case of relapsing babesiosis. Here, we report 5 cases of relapsing babesiosis treated with tafenoquine, including the previous case, and begin to define the conditions for optimal use of tafenoquine in relapsing babesiosis. Methods. A definitive diagnosis of babesiosis was made by microscopic examination of Giemsa-stained thin blood smears or a real-time polymerase chain reaction (PCR) that targets the parasite 18S rRNA gene. Clearance of B. microti infection was ascertained by use of blood smear and real-time PCR. Results. Tafenoquine was initiated with a loading dose of 600 mg. A weekly maintenance dose consisted of 200 mg or 300 mg; the lower dose was associated with a delayed clearance of B. microti. In 2 cases, all antimicrobial agents but tafenoquine were discontinued prior to clearance of infection. In 2 other cases, clearance was achieved while tafenoquine was administered along with other antimicrobial agents. In 3 of these 4 cases, tafenoquine was used in combination with atovaquone-proguanil. Other agents included atovaquone, azithromycin, and/or clindamycin. In 1 case, tafenoquine was administered alone and failed to prevent relapse. Conclusions. Tafenoquine can be a useful adjunct for the treatment of highly immunocompromised patients experiencing relapsing babesiosis caused by B. microti. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. |
| Keywords: | relapse; immunocompromised; babesiosis; babesia microti; tafenoquine |
| Journal Title: | Clinical Infectious Diseases |
| Volume: | 79 |
| Issue: | 1 |
| ISSN: | 1058-4838 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-07-15 |
| Start Page: | 130 |
| End Page: | 137 |
| Language: | English |
| DOI: | 10.1093/cid/ciae238 |
| PUBMED: | 38814096 |
| PROVIDER: | scopus |
| PMCID: | PMC11259219 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work